Skip to main content

Published locations for Doctors hesitated to embrace biosimilar infliximab in first 2 years

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Doctors hesitated to embrace biosimilar infliximab in first 2 years

User login

  • Reset your password
  • /content/doctors-hesitated-embrace-biosimilar-infliximab-first-2-years
  • /edermatologynews/article/225659/rheumatoid-arthritis/doctors-hesitated-embrace-biosimilar-infliximab
  • /familypracticenews/article/225659/rheumatoid-arthritis/doctors-hesitated-embrace-biosimilar
  • /internalmedicinenews/article/225659/rheumatoid-arthritis/doctors-hesitated-embrace-biosimilar
  • /rheumatologynews/article/225659/rheumatoid-arthritis/doctors-hesitated-embrace-biosimilar-infliximab
  • /jcomjournal/article/225659/rheumatoid-arthritis/doctors-hesitated-embrace-biosimilar-infliximab
  • /rheumatology/article/225659/rheumatoid-arthritis/doctors-hesitated-embrace-biosimilar-infliximab
  • /internalmedicine/article/225659/rheumatoid-arthritis/doctors-hesitated-embrace-biosimilar-infliximab
  • /dermatology/article/225659/rheumatoid-arthritis/doctors-hesitated-embrace-biosimilar-infliximab
  • /familymedicine/article/225659/rheumatoid-arthritis/doctors-hesitated-embrace-biosimilar-infliximab
  • /rheumatology/psoriatic-arthritis-resource-center/article/225659/rheumatoid-arthritis/doctors
  • /psoriatic-arthritis-icymi/article/225659/rheumatoid-arthritis/doctors-hesitated-embrace-biosimilar